Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07825064) titled 'Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hoffmann-La Roche
Condition:
Multiple Myeloma
Intervention:
Drug: Cevostamab
Drug: Pomalidomide
Drug: Dexamethasone
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 45
Countries of Recruitment:
Germa...